Tremelimumab price list

Tremelimumab is an immune checkpoint inhibitor targeting T cells and belongs to the anti-CTLA-4 monoclonal antibody class. The original intention of its development is to enhance the body's immune response to tumor cells by blocking the binding of CTLA-4 to its ligands and releasing the negative regulation of T cells. With the popularization of the concept of immunotherapy, temsitumumab has gradually gained attention in clinical application, especially showing certain potential in the treatment of hepatocellular carcinoma and non-small cell lung cancer. In October 2022, the US FDA officially approved temsitumumab combined with durvalumab (Durvalumab) for patients with unresectable hepatocellular carcinoma, which is one of its important indications. In addition, in the field of advanced non-small cell lung cancer, the treatment model of temsitumumab and durvalumab combined with platinum-based chemotherapy provides new treatment hope for patients who previously lacked effective options.

From a price point of view, temsitumumab is not currently available in mainland China and therefore cannot be included in the medical insurance system. in the country, if patients need to use it, they need to rely on Hong Kong or other overseas channels. According to public information, the specification of temsitumumab in Hong Kong is 300mg/15ml, and the price is about 100,000 yuan. This price still poses a considerable burden to patients, especially when long-term combined medication is required, and the economic pressure is even more prominent. At the same time, there are currently no generic drugs on the market, which means there is little room for price decline in the short term. If it enters the Chinese mainland market in the future and is included in the medical insurance catalog, it will be possible to achieve a significant price reduction, thereby benefiting more patients.

Generally speaking, the application of temsitumumab is mainly concentrated in the field of immune combination therapy. The price is higher but it reflects the value of innovative drugs. As the concept of immunotherapy continues to deepen in China's cancer treatment system, if the drug can be approved for domestic marketing in the future and successfully negotiate with medical insurance, it will have a positive impact on the treatment pattern for patients with liver cancer and lung cancer.

Reference: https://www.drugs.com/mtm/tremelimumab.html